Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02303392 · ClinicalTrials.gov registry record · Phase 1
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Jennifer Woyach.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02303392 is a Phase 1 study that has completed, run by Jennifer Woyach. The registered enrollment target is 34 participants.
The verdict
NCT02303392, a Phase 1 study, has completed, sponsored by Jennifer Woyach.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of selinexor when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or aggressive non-Hodgkin lymphoma that has returned after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor together with ibrutinib may be a better treatment for chronic lymphocytic leukemia or aggressive non-Hodgkin lymphoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Selinexor
- DRUG Ibrutinib
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-06-09 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02303392
The ClinicalTrials.gov registry entry for NCT02303392 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jennifer Woyach, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02303392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02303392 about?
NCT02303392 is a clinical study titled "Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma". This phase I trial studies the side effects and best dose of selinexor when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or aggressive non-Hodgkin lymphoma that has returned after a period of improvement or does not respond to treatment. Drugs used in chemothe...
What is the current status of trial NCT02303392?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2015-06-09. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT02303392?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Selinexor (DRUG), Ibrutinib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02303392?
This trial is sponsored by Jennifer Woyach, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.